LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

Home・Elenco Azioni・Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics Inc

Chiusa

SettoreSettore sanitario

20.65 -2.64

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

20.23

Massimo

21.31

Metriche Chiave
By Trading Economics
Entrata	10M 17M
Vendite	30M 130M
EPS	0.13
Margine di Profitto	13.432
Dipendenti	354
EBITDA	11M 22M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+63.04% upside

Dividendi
By Dow Jones
Utili prossimi	5 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-285M 2.9B
Apertura precedente	23.29
Chiusura precedente	20.65

Notizie sul Sentiment di mercato

By Acuity

50%

150 / 346 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bearish Evidence

12.42 / 14.93 Supporto e resistenza

Arcutis Biotherapeutics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

12 mag 2026, 22:50 UTC

Utili

Commonwealth Bank of Australia Increases Provisions as 3Q Profit Slips

12 mag 2026, 22:49 UTC

Utili

Aristocrat Leisure Raises Midyear Dividend, Swells Share Buyback Program

12 mag 2026, 22:32 UTC

Utili

JBS 1Q Profit Slides Amid Rising Cattle Costs -- Update

12 mag 2026, 23:48 UTC

Discorsi di Mercato

Nikkei May Decline Amid Uncertainty Over Iran Conflict -- Market Talk

12 mag 2026, 22:57 UTC

Discorsi di Mercato

Utili

JBS Says Consumers Are Looking to Pork for Affordable Protein -- Market Talk

12 mag 2026, 22:26 UTC

Utili

Aristocrat Leisure to Increase On-Market Share Buyback by A$1 Billion

12 mag 2026, 22:25 UTC

Utili

Aristocrat Leisure 1H Normalized Pretax Profit A$997.3 Million, Up 9.4% on Year

12 mag 2026, 22:25 UTC

Utili

Aristocrat Leisure Interim Dividend A$0.50/Security

12 mag 2026, 22:24 UTC

Utili

Aristocrat Leisure 1H Revenue From Continuing Operations A$3.03 Billion, Down 0.2% on Year

12 mag 2026, 22:23 UTC

Utili

Aristocrat Leisure 1H Net Profit From Discontinued Operations A$7.0 Million

12 mag 2026, 22:23 UTC

Utili

Aristocrat Leisure 1H Net Profit From Continuing Operations A$798.5 Million, Up 56%

12 mag 2026, 22:19 UTC

Utili

CBA: Total Provision Coverage Ratio 1.57%>CBA.AU

12 mag 2026, 22:14 UTC

Utili

CBA: Business Lending Continued to Grow Above System>CBA.AU

12 mag 2026, 22:14 UTC

Utili

CBA Had 1.4M Business Transaction Accounts at March 31, Up 7% on Year>CBA.AU

12 mag 2026, 22:13 UTC

Utili

CBA Household Deposits Grew A$38B in 12 Months Through March>CBA.AU

12 mag 2026, 22:12 UTC

Utili

CBA Home Loan Balances Grew A$41B in 12 Months Through March>CBA.AU

12 mag 2026, 22:12 UTC

Utili

CBA 3Q New Home Loan Funding A$45B>CBA.AU

12 mag 2026, 22:11 UTC

Utili

Correct: JBS NV 1Q EPS 20c, Not 21c >JBS

12 mag 2026, 22:11 UTC

Utili

CBA: CET1 Level 2 Capital Ratio 11.6%>CBA.AU

12 mag 2026, 22:10 UTC

Utili

CBA: Customer Deposit Funding Ratio 79%>CBA.AU

12 mag 2026, 22:09 UTC

Utili

CBA: Underlying Portfolio Credit Quality Remains Sound>CBA.AU

12 mag 2026, 22:09 UTC

Utili

CBA: Higher Collective Provisions Reflect Geopolitical, Macroeconomic Uncertainty >CBA.AU

12 mag 2026, 22:08 UTC

Utili

CBA 3Q Loan Impairment Expense A$316M>CBA.AU

12 mag 2026, 22:07 UTC

Utili

CBA: Costs Up on Higher Cloud Computing Volumes, Software Licenses, AI Investment>CBA.AU

12 mag 2026, 22:06 UTC

Utili

CBA 3Q Operating Expenses Up 1% Excluding Restructuring, Notable Items>CBA.AU

12 mag 2026, 22:06 UTC

Utili

CBA: 3Q Underlying Net Interest Margin Was Broadly Stable>CBA.AU

12 mag 2026, 22:05 UTC

Utili

CBA: Lending, Deposit Volume Growth Offset Impact of Two Fewer Days >CBA.AU

12 mag 2026, 22:04 UTC

Utili

Commonwealth Bank: Operating Income Flat in March Quarter >CBA.AU

12 mag 2026, 22:04 UTC

Utili

Commonwealth Bank 3Q Cash Profit Up 4% on Year>CBA.AU

12 mag 2026, 22:04 UTC

Utili

Commonwealth Bank 3Q Cash Profit Down 1% on 1H Quarterly Average>CBA.AU

Confronto tra pari

Modifica del prezzo

Arcutis Biotherapeutics Inc Previsione

Obiettivo di Prezzo

By TipRanks

63.04% in crescita

Previsioni per 12 mesi

Media 34.63 USD 63.04%

Alto 36 USD

Basso 33 USD

Basato su 8 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Arcutis Biotherapeutics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

8 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 8 che hanno fornito valutazioni azionarie a Arcutis Biotherapeutics Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

12.42 / 14.93Supporto e resistenza

Recent bearish events outweigh bullish events.

There is one bullish event.

Sentiment

By Acuity

150 / 346 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.